Investors who hold shares of Sage Therapeutics, Inc. (NASDAQ: SAGE) Long Term should contact the Shareholders Foundation in connection with Investigation

An investigation was announced for long-term investors in shares of Sage Therapeutics, Inc. (NASDAQ: SAGE) concerning potential breaches of fiduciary duties by certain directors of Sage Therapeutics, Inc.

Investors who are current long term investors in Sage Therapeutics, Inc. (NASDAQ: SAGE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: SAGE stocks follows a lawsuit filed against Sage Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: SAGE stocks, concerns whether certain Sage Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that zuranolone was less effective in treating MDD than Defendants had led investors to believe, that accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone's clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated, that SAGE-718 was less effective in treating MCI due to PD than Defendants had led investors to believe, that accordingly, SAGE-718's clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated, that SAGE-324 was less effective in treating ET than Defendants had led investors to believe, thataccordingly, SAGE-324's clinical, regulatory, and commercial prospects as a treatment for ET were overstated, and that as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Sage Therapeutics, Inc. (NASDAQ: SAGE) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.